Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2010

Open Access 01-12-2010 | Original investigation

Intracellular Ca2+ regulating proteins in vascular smooth muscle cells are altered with type 1 diabetes due to the direct effects of hyperglycemia

Authors: Yvonne M Searls, Rajprasad Loganathan, Irina V Smirnova, Lisa Stehno-Bittel

Published in: Cardiovascular Diabetology | Issue 1/2010

Login to get access

Abstract

Background

Diminished calcium (Ca2+) transients in response to physiological agonists have been reported in vascular smooth muscle cells (VSMCs) from diabetic animals. However, the mechanism responsible was unclear.

Methodology/Principal Findings

VSMCs from autoimmune type 1 Diabetes Resistant Bio-Breeding (DR-BB) rats and streptozotocin-induced rats were examined for levels and distribution of inositol trisphosphate receptors (IP3R) and the SR Ca2+ pumps (SERCA 2 and 3). Generally, a decrease in IP3R levels and dramatic increase in ryanodine receptor (RyR) levels were noted in the aortic samples from diabetic animals. Redistribution of the specific IP3R subtypes was dependent on the rat model. SERCA 2 was redistributed to a peri-nuclear pattern that was more prominent in the DR-BB diabetic rat aorta than the STZ diabetic rat. The free intracellular Ca2+ in freshly dispersed VSMCs from control and diabetic animals was monitored using ratiometric Ca2+ sensitive fluorophores viewed by confocal microscopy. In control VSMCs, basal fluorescence levels were significantly higher in the nucleus relative to the cytoplasm, while in diabetic VSMCs they were essentially the same. Vasopressin induced a predictable increase in free intracellular Ca2+ in the VSMCs from control rats with a prolonged and significantly blunted response in the diabetic VSMCs. A slow rise in free intracellular Ca2+ in response to thapsigargin, a specific blocker of SERCA was seen in the control VSMCs but was significantly delayed and prolonged in cells from diabetic rats. To determine whether the changes were due to the direct effects of hyperglycemica, experiments were repeated using cultured rat aortic smooth muscle cells (A7r5) grown in hyperglycemic and control conditions. In general, they demonstrated the same changes in protein levels and distribution as well as the blunted Ca2+ responses to vasopressin and thapsigargin as noted in the cells from diabetic animals.

Conclusions/Significance

This work demonstrates that the previously-reported reduced Ca2+ signaling in VSMCs from diabetic animals is related to decreases and/or redistribution in the IP3R Ca2+ channels and SERCA proteins. These changes can be duplicated in culture with high glucose levels.
Appendix
Available only for authorised users
Literature
1.
Preis S, Hwang S, Coady S, Pencina M, D'Agostino RS, Savage P, Levy D, Fox C: Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. Circulation. 2009, 119: 1728-1735. 10.1161/CIRCULATIONAHA.108.829176.PubMedCentralCrossRefPubMed
2.
Soedamah-Muthu S, Stehouwer C: Cardiovascular disease morbidity and mortality in patients with type 1 diabetes mellitus: management strategies. Treat Endocrinol. 2005, 4: 75-86. 10.2165/00024677-200504020-00002.CrossRefPubMed
3.
Aronson D: Hyperglycemia and the pathobiology of diabetic complications. Adv Cardiol. 2008, 45: 1-16. full_text.CrossRefPubMed
4.
Laing S, Swerdlow A, Slater S, Burden A, Morris A, Waugh N, Gatling W, Bingley P, Patterson C: Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia. 2003, 46: 760-765. 10.1007/s00125-003-1116-6.CrossRefPubMed
5.
Luscher T, Creager M, Beckman J, Cosentino F: Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Circulation. 2003, 108: 1655-1661. 10.1161/01.CIR.0000089189.70578.E2.CrossRefPubMed
6.
Aksnes T, Kjeldsen S, Rostrup M, Omvik P, Hua T, Julius S: Impact of new onset diabetes mellitus on cardiac outcomes in the Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial population. Hypertension. 2007, 50 (3): 467-473. 10.1161/HYPERTENSIONAHA.106.085654.CrossRefPubMed
7.
Soedamah-Muthu S, Chaturvedi N, Witte D, Stevens L, Porta M, Fuller J, Group EPCS: Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008, 31: 1360-1366. 10.2337/dc08-0107.PubMedCentralCrossRefPubMed
8.
Putaala J, Curtze S, Hiltunen S, Tolppanen H, Kaste M, Tatlisumak T: Causes of death and predictors of 5-year mortality in young adults after first-ever ischemic stroke: the Helsinki Young Stroke Registry. Stroke. 2009, 40: 2698-2703. 10.1161/STROKEAHA.109.554998.CrossRefPubMed
9.
10.
Karastergiou K, Kaski J: Medical management of the diabetic patient with coronary artery disease. Curr Pharm Des. 2008, 14: 2527-2536. 10.2174/138161208786071272.CrossRefPubMed
11.
Nacci C, Tarquinio M, De Benedictis L, Mauro A, Zigrino A, Carratù M, Quon M, Montagnani M: Endothelial dysfunction in mice with streptozotocin-induced type 1 diabetes is opposed by compensatory overexpression of cyclooxygenase-2 in the vasculature. Endocrinology. 2009, 150: 849-861. 10.1210/en.2008-1069.PubMedCentralCrossRefPubMed
12.
Bjarnegård N, Arnqvist H, Lindström T, Jonasson L, Jönsson A, Länne T: Long term hyperglycaemia impairs vascular smooth muscle cell function in women with type 1 diabetes mellitus. Diab Vasc Dis Res. 2009, 6: 25-31. 10.3132/dvdr.2009.005.CrossRefPubMed
13.
Dunn K, Nelsom M: Calcium and diabetic vascular dysfunction. Focus on "Elevated Ca2+ sparklet activity during acute hyperglycemia and diabetes in cerebral arterial smooth muscle. Am J Physiol Cell Physiol. 2010, 298: C203-C205.CrossRefPubMed
14.
Madi H, Riches K, Warburton P, O'Regan D, Turner N, Porter K: Inherent differences in morphology, proliferation, and migration in saphenous vein smooth muscle cells cultured from nondiabetic and Type 2 diabetic patients. Am J Physiol Cell Physiol. 2009, 297: C1307-1317. 10.1152/ajpcell.00608.2008.CrossRefPubMed
15.
16.
Faries PL, Rohan DI, Takahara H, Wyers MC, Contreras MA, Quist WC, King GL, Logerfo FW: Human vascular smooth muscle cells of diabetic origin exhibit increased proliferation, adhesion, and migration. J Vasc Surg. 2001, 33: 601-607. 10.1067/mva.2001.111806.CrossRefPubMed
17.
Vranes D, Cooper ME, Dilley RJ: Cellular mechanisms of diabetic vascular hypertrophy. Microvasc Res. 1999, 57: 8-18. 10.1006/mvre.1998.2107.CrossRefPubMed
18.
Haddock R, Hill C: Differential activation of ion channels by inositol 1,4,5-trisphosphate (IP3)- and ryanodine-sensitive calcium stores in rat basilar artery vasomotion. J Physiol. 2002, 545: 615-627. 10.1113/jphysiol.2002.027904.PubMedCentralCrossRefPubMed
19.
Descorbeth M, Anand-Srivastava M: High glucose increases the expression of Gq/11alpha and PLC-beta proteins and associated signaling in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 2008, 295: H2135-2142. 10.1152/ajpheart.00704.2008.CrossRefPubMed
20.
Sharma K, Deelman L, Madesh M, Kurz B, Ciccone E, Siva S, Hu T, Zhu Y, Wang L, Henning R: Involvement of transforming growth factor-beta in regulation of calcium transients in diabetic vascular smooth muscle cells. Am J Physiol Renal Physiol. 2003, 285: F1258-1270.CrossRefPubMed
21.
Kinoshita Y, Ito H, Hirano A, Fujita K, Wate R, Nakamura M, Kaneko S, Nakano S, Kusaka H: Nuclear contour irregularity and abnormal transporter protein distribution in anterior horn cells in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2009, 68: 1184-1192. 10.1097/NEN.0b013e3181bc3bec.CrossRefPubMed
22.
Fedoryak O, Searls Y, Smirnova I, Burns D, Stehno-Bittel L: Spontaneous Ca2+ oscillations in subcellular compartments of vascular smooth muscle cells rely on different Ca2+ pools. Cell Res. 2004, 14: 379-388. 10.1038/sj.cr.7290238.CrossRefPubMed
23.
Tasker PN, Taylor CW, Nixon GF: Expression and distribution of InsP(3) receptor subtypes in proliferating vascular smooth muscle cells. Biochem Biophys Res Commun. 2000, 273: 907-912. 10.1006/bbrc.2000.3036.CrossRefPubMed
24.
Abrenica B, Pierce GN, Gilchrist JS: Nucleoplasmic calcium regulation in rabbit aortic vascular smooth muscle cells. Can J Physiol Pharmacol. 2003, 81: 301-310. 10.1139/y03-005.CrossRefPubMed
25.
Vermassen E, Van Acker K, Annaert WG, Himpens B, Callewaert G, Missiaen L, De Smedt H, Parys JB: Microtubule-dependent redistribution of the type-1 inositol 1,4,5-trisphosphate receptor in A7r5 smooth muscle cells. J Cell Sci. 2003, 116: 1269-1277. 10.1242/jcs.00354.CrossRefPubMed
26.
Kim HW, Ch YS, Lee HR, Park SY, Kim YH: Diabetic alterations in cardiac sarcoplasmic reticulum Ca2+-ATPase and phospholamban protein expression. Life Sci. 2001, 70: 367-379. 10.1016/S0024-3205(01)01483-7.CrossRefPubMed
27.
Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft SJ, Turner R: Sequence variants of the sarco(endo)plasmic reticulum Ca(2+)-transport ATPase 3 gene (SERCA3) in Caucasian type II diabetic patients (UK Prospective Diabetes Study 48). Diabetologia. 1999, 42: 1240-1243. 10.1007/s001250051298.CrossRefPubMed
28.
Ma L, Zhu B, Chen X, Liu J, Guan Y, Ren J: Abnormalities of sarcoplasmic reticulum Ca2+ mobilization in aortic smooth muscle cells from streptozotocin-induced diabetic rats. Clin Exp Pharmacol Physiol. 2008, 35: 568-573. 10.1111/j.1440-1681.2007.04832.x.CrossRefPubMed
29.
Sakai Y, Kwan CY: Calcium regulation and contractile dysfunction of smooth muscle. Biol Signals. 1993, 2: 305-312. 10.1159/000109511.CrossRefPubMed
30.
Wang R, Wu Y, Tang G, Wu L, Hanna ST: Altered L-type Ca(2+) channel currents in vascular smooth muscle cells from experimental diabetic rats. Am J Physiol Heart Circ Physiol. 2000, 278: H714-722.PubMed
31.
Wu SN, Yu HS, Seyama Y: Analytical studies of spontaneous and vasopressin-induced calcium oscillations in cultured vascular smooth muscle cells. J Biochem. 1996, 119 (1): 42-48.CrossRefPubMed
32.
Pucovský V, Bolton T: Localisation, function and composition of primary Ca(2+) spark discharge region in isolated smooth muscle cells from guinea-pig mesenteric arteries. Cell Calcium. 2006, 39: 113-129. 10.1016/j.ceca.2005.10.002.CrossRefPubMed
33.
34.
van Breemen C, Saida K: Cellular mechanisms regulating [Ca2+i] smooth muscle. Annu Rev Physiol. 1989, 51: 315-329. 10.1146/annurev.physiol.51.1.315.CrossRefPubMed
35.
Tong X, Ying J, Pimentel D, Trucillo M, Adachi T, Cohen R: High glucose oxidizes SERCA cysteine-674 and prevents inhibition by nitric oxide of smooth muscle cell migration. J Mol Cell Cardiol. 2008, 44: 361-369. 10.1016/j.yjmcc.2007.10.022.PubMedCentralCrossRefPubMed
36.
Ying J, Sharov V, Xu S, Jiang B, Gerrity R, Schöneich C, Cohen R: Cysteine-674 oxidation and degradation of sarcoplasmic reticulum Ca(2+) ATPase in diabetic pig aorta. Free Radic Biol Med. 2008, 45: 756-762. 10.1016/j.freeradbiomed.2008.05.029.PubMedCentralCrossRefPubMed
37.
Wu KD, Bungard D, Lytton J: Regulation of SERCA Ca2+ pump expression by cytoplasmic Ca2+ in vascular smooth muscle cells. Am J Physiol Cell Physiol. 2001, 280: C843-851.PubMed
38.
David K, Scott R, Nixon G: Advanced glycation endproducts induce a proliferative response in vascular smooth muscle cells via altered calcium signaling. Biochem Pharmacol. 2008, 76: 1110-1120. 10.1016/j.bcp.2008.08.011.CrossRefPubMed
39.
Martin V, Bredoux R, Corvazier E, Van Gorp R, Kovacs T, Gelebart P, Enouf J: Three novel sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) 3 isoforms. Expression, regulation, and function of the membranes of the SERCA3 family. J Biol Chem. 2002, 277: 24442-24452. 10.1074/jbc.M202011200.CrossRefPubMed
40.
Hadri L, Pavoine C, Lipskaia L, Yacoubi S, Lompré A: Transcription of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase type 3 gene, ATP2A3, is regulated by the calcineurin/NFAT pathway in endothelial cells. Biochem J. 2006, 394: 27-33. 10.1042/BJ20051387.PubMedCentralCrossRefPubMed
41.
Varadi A, Lebel L, Hashim Y, Mehta Z, Ashcroft S, Turner R: Sequence variants of the sarco(endo)plasmic reticulum Ca(2+)-transport ATPase 3 gene (SERCA3) in Caucasian type II diabetic patients (UK Prospective Diabetes Study 48). Diabetologia. 1999, 42: 1240-1243. 10.1007/s001250051298.CrossRefPubMed
42.
Jaffer U, Aslam M, Standfield N: Impaired hyperaemic and rhythmic vasomotor response in type 1 diabetes mellitus patients: a predictor of early peripheral vascular disease. Eur J Vasc Endovasc Surg. 2008, 35: 603-606. 10.1016/j.ejvs.2007.12.006.CrossRefPubMed
43.
Gurney A, Howarth F: Effects of streptozotocin-induced diabetes on the pharmacology of rat conduit and resistance intrapulmonary arteries. Cardiovasc Diabetol. 2009, doi: 10.1186/1475-2840-8-4
44.
Hill B, Price E, Dixon J, Sturek M: Increased calcium buffering in coronary smooth muscle cells from diabetic dyslipidemic pigs. Atherosclerosis. 2003, 167: 15-23. 10.1016/S0021-9150(02)00381-7.CrossRefPubMed
45.
McGowan TA, Sharma K: Regulation of inositol 1,4,5-trisphosphate receptors by transforming growth factor-beta: implications for vascular dysfunction in diabetes. Kidney Int Suppl. 2000, 77: S99-103. 10.1046/j.1523-1755.2000.07716.x.CrossRefPubMed
46.
Misquitta C, Chen T, Grover A: Control of protein expression through mRNA stability in calcium signalling. Cell Calcium. 2006, 40: 329-346. 10.1016/j.ceca.2006.04.004.CrossRefPubMed
47.
Nilsson J, Nilsson L, Chen Y, Molkentin J, Erlinge D, Gomez M: High glucose activates nuclear factor of activated T cells in native vascular smooth muscle. Arterioscler Thromb Vasc Biol. 2006, 26: 794-800. 10.1161/01.ATV.0000209513.00765.13.CrossRefPubMed
48.
Schaeffer G, Levak-Frank S, Spitaler M, Fleischhacker E, Esenabhalu V, Wagner A, Hecker M, Graier WF: Intercellular signalling within vascular cells under high D-glucose involves free radical-triggered tyrosine kinase activation. Diabetologia. 2003, 46: 773-783. 10.1007/s00125-003-1091-y.CrossRefPubMed
49.
Bkaily G, Choufani S, Avedanianm L, Ahmarani L, Nader M, Jacques D, D'Orléans-Juste P, Al Khoury J: Nonpeptidic antagonists of ETA and ETB receptors reverse the ET-1-induced sustained increase of cytosolic and nuclear calcium in human aortic vascular smooth muscle cells. Can J Physiol Pharmacol. 2008, 86: 546-556. 10.1139/Y08-048.CrossRefPubMed
50.
Bkaily G, Nader M, Avedanian L, Choufani S, Jacques D, D'Orléans-Juste P, Gobeil F, Chemtob S, Al-Khoury J: G-protein-coupled receptors, channels, and Na+-H+ exchanger in nuclear membranes of heart, hepatic, vascular endothelial, and smooth muscle cells. Can J Physiol Pharmacol. 2006, 84: 431-441. 10.1139/Y06-002.CrossRefPubMed
51.
Leite MF, Thrower EC, Echevarria W, Koulen P, Hirata K, Bennett AM, Ehrlich BE, Nathanson MH: Nuclear and cytosolic calcium are regulated independently. Proc Natl Acad Sci USA. 2003, 100: 2975-2980. 10.1073/pnas.0536590100.PubMedCentralCrossRefPubMed
52.
Stehno-Bittel L, Luckhoff A, Clapham DE: Calcium release from the nucleus by InsP3 receptor channels. Neuron. 1995, 14: 163-167. 10.1016/0896-6273(95)90250-3.CrossRefPubMed
53.
Kinnear N, Wyatt C, Clark J, Calcraft P, Fleischer S, Jeyakumar L, Nixon G, Evans A: Lysosomes co-localize with ryanodine receptor subtype 3 to form a trigger zone for calcium signalling by NAADP in rat pulmonary arterial smooth muscle. Cell Calcium. 2008, 44: 190-201. 10.1016/j.ceca.2007.11.003.PubMedCentralCrossRefPubMed
54.
Papadia S, Stevenson P, Hardingham N, Bading H, Hardingham G: Nuclear Ca2+ and the cAMP response element-binding protein family mediate a late phase of activity-dependent neuroprotection. J Neurosci. 2005, 25 (17): 4279-4287. 10.1523/JNEUROSCI.5019-04.2005.CrossRefPubMed
55.
Lau D, Bading H: Synaptic activity-mediated suppression of p53 and induction of nuclear calcium-regulated neuroprotective genes promote survival through inhibition of mitochondrial permeability transition. J Neurosci. 2009, 29: 4420-4429. 10.1523/JNEUROSCI.0802-09.2009.CrossRefPubMed
Metadata
Title
Intracellular Ca2+ regulating proteins in vascular smooth muscle cells are altered with type 1 diabetes due to the direct effects of hyperglycemia
Authors
Yvonne M Searls
Rajprasad Loganathan
Irina V Smirnova
Lisa Stehno-Bittel
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2010
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-9-8

Other articles of this Issue 1/2010

Cardiovascular Diabetology 1/2010 Go to the issue

Original investigation

Long-term prognosis of diabetic patients with acute myocardial infarction in the era of acute revascularization

Original investigation

Chromosome 9p21.3 polymorphism in a Chinese Han population is associated with angiographic coronary plaque progression in non-diabetic but not in type 2 diabetic patients

Original investigation

Adiponectin, resistin and IL-6 plasma levels in subjects with diabetic foot and possible correlations with clinical variables and cardiovascular co-morbidity

Original investigation

Rosiglitazone reverses endothelial dysfunction but not remodeling of femoral artery in Zucker diabetic fatty rats

Review

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

Editorial

The ubiquitous interleukin-6: a time for reappraisal
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits